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Abstract
Background: Either classic or novel biomarkers have not been well investigated for clinical outcomes of coronary
artery disease (CAD) in Asian people especially ethnic Chinese. We reported here a prospective national-based follow-up
study that aims to elucidate the clinical profiles and to identify the new biosignatures (especially the non-lipid profile and
inflammatory biomakers) for future clinical outcomes in a sizable cohort of stable CAD patients in Taiwan.
Methods: A total of 2500 CAD patients under stable condition after successful percutaneous coronary intervention will
be enrolled for clinical data collection and blood/urine sampling in northern, southern, western, or eastern part of Taiwan
between 2012 and 2017. They will be regularly followed up at least annually for 5 years to assess all cause deaths, hard
clinical events (including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke), and total cardiovascular
events (including hard events, unplanned revascularization procedures, unplanned hospitalization for refractory or unstable
angina, and for other causes such as stroke, transient ischemic attack, heart failure, or peripheral arterial occlusive disease).
The classic and newly defined biosignatures will be compared in patients with and without clinical events
during follow-up. The novel biomarkers will be identified via metabolomics analyses. Additionally, psychological personality
and lifestyle data will be incorporated to explore the new dimensional views of the complex mechanisms of the disease.
Till December 2014, the initial 1663 patients have been successfully enrolled. Among them, 85.93% are male; 36.22% have
type 2 diabetes; 64.82% have hypertension; 56.04% are smokers and 20.44% have a family history of CAD. Their lipid
profiles are under contemporary medical control with a mean plasma total cholesterol level of 163.51 ± 36.99 mg/dL
and a mean low-density lipoprotein cholesterol level of 95.21 ± 29.98 mg/dL.
Discussion: This nationwide study has successfully started to update the contemporary information and to investigate
the potential predictors for clinical outcomes of stable CAD patients in Taiwan. The identification of new biomarkers,
lifestyle and psychological personality may help to elucidate the complex mechanisms and provide the novel rational
to the individual treatment strategies in Asian especially ethnic Chinese patients with CAD.
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Background
Cardiovascular (CV) disease, a common disease in
developed countries is associated with increased risk of
mortality and morbidity, and is the leading cause of
death worldwide. It has beensuggested that atheroscler-
osis plays a central role in CV disease. A chronic inflam-
matory process in the vessels leads to vascular damage,
atheroma formation, vessel occlusion and even plaque
rupture during the progression of atherosclerosis.
Despite great efforts including the development of new
medical devices, more aggressive revascularization
therapies as well as progress in medication, the inci-
dence of events associated with coronary artery disease
(CAD) such as acute coronary syndrome (ACS), stroke,
cardiac death, and revascularization persists, especially
in high-risk CAD patients after coronary intervention. It
has been shown that the severity of coronary arterial
stenosis could not completely predict the risk of plaque
rupture and the occurrence of subsequent thrombosis. A
clinical risk score such as the Framingham risk score has
been generated to predict cardiac risk, but it cannot
reveal the whole disease risk for an Asian population and
may lose its predictive value in a population with inter-
mediate risk. The geographic heterogeneity, the genetic
susceptibility, dietary habit and environmental risk expos-
ure further increased the complexity of using same risk
scoring to predict future risk for patients with CAD. It
then becomes important to reassess the clinical profile
and the diagnostic and treatment strategies in different
cohorts, and to identify indicators for high-risk patients
both in the general and the local clinical background.
Disease-specific biosignatures have a biological charac-
teristic that can be measured and evaluated objectively
as an indicator of normal biological process, pathogenic
process, or pharmacological response to a therapeutic
intervention [1]. Biomarkers, as a part of the biosigna-
tures, can be used for a disease at different stages which
may be associated with its onset, clinical course, or
response to treatment [2–4]. For CV diseases, circulating
biomarkers that have been incorporated into clinical
practice are mainly used asprognostic markers, and have
been shown to have value in addition to classic CV risk
factors, which include N-terminal pro-B-type Natriuretic
Peptide (NT-proBNP) for heart failure [5], glycated
haemoglobin (HbA1c) for glycaemic control in diabetes
[6], high-sensitivity TroponinI [7], and high-sensitivity
C-Reactive Protein (hs-CRP) for CV risk prediction [8].
Among them, inflammatory related biomarkers such as
hs-CRP have been shown useful particularly for CAD
patients with intermediate risk [8]. However, further data
are still required to examine the specificity and efficacy
of these new biomarkers for their clinical implication in
different disease severity and in patients of different
races in the world.
On the other hand, current treatment of CV disease
adheres to tight guidelines. While classic risk factors
such as blood pressure, sugar and lipid profile are
treated accordingly, future adverse event rate remains
high in some well-controlled patients, indicating the
possibility of residual risks that need to be targeted,
and which may also be related to the lack of more
specific and powerful prognostic biomarkers to iden-
tify those patients at particular risk. For example, the
interaction between personal factors, life styles, and
classic risk factors may be complex. On the other
hand, the identification of inflammatory biomarkers
may be of value to follow the progression of vascular
inflammation in atherosclerosis. Therefore, the role of
clinical consortia and biospecimen banks is crucial for
further investigations. Recent studies have also
pointed to the potential of new strategies such as
metabolomics or proteomics for novel biomarkers in
the investigation of CV disease [9].
Finally, given the potential difference in diet, culture,
and physical background between Western and Asian
people, either classic or new biomarkers have not been
well investigated for clinical outcomes in Asian patients
especially ethnic Chinese with stable CAD. Therefore,
we conduct a prospective follow-up study on a national
basis to evaluate the demographic data, clinical profiles,
and treatment strategies for future CV events in stable
CAD patients under contemporary treatment in Taiwan.
The collected data will be also used to stratify patients at
particular future risk by identifying new biosignature
profiles such as novel inflammatory biomarkers and the
novel biomarkers via metabolomics approach. Here we
present the study design/protocol together with the
baseline data including demographic characteristics,




A consortium has been organized to conduct this study.
Principle investigator meeting of consortium has been
held every two months to discuss any queries about the
protocol setting, IRB review process, and cases recruit-
ment. In addition, Professor Ueng-Cheng Yang in
National Yang-Ming University and Professor Wen-Harn
Pan in Academia Sinica helped to build up the Clinical In-
formatics & Management System and sample collecting
protocol for our consortium. Training courses for data
collection were hold for four times. The objectives of the
training sessions were not only to produce an instrument
for this study but also to instruct the CAD in the princi-
ples of instrument design and to elaborate an instrument
that could be standardized for use in later CAD research
projects. All information will be recorded and blood/urine
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sample are stored in a central Laboratory in National
Yang-Ming University, Taipei, Taiwan.
Study protocol
Patient enrollment
A series of stable CAD patients was initially evaluated in
nine different medical centers located in Northern,
Central, Southern, and Eastern Taiwan. The patients
were initially evaluated if they had a history of significant
CAD, as documented by coronary angiogram, a history
of myocardial infarction as evidenced by 12-lead electro-
cardiography (ECG) or hospitalization, or a history of
angina with ischemic ECG changes or positive response
to stress test. The patients were enrolled only if (1) they
had received successful percutaneous coronary interven-
tion (PCI) with either coronary stenting or balloon
angioplasty at least once previously, and (2) they had
been stable on medical treatment for at least 1 month
before enrollment.
Exclusion criteria
Patients were excluded if (1) they had been hospitalized
for unstable angina, acute coronary syndrome, acute
myocardial infarction, acute cerebrovascular events, or
other acute cardiovascular events within the 3 months
prior to enrollment, (2) they planned to receive further
coronary revascularization or interventional procedures
for other CV diseases during the following one year
period, (3) they had significant malignancy or tumor
diseases requiring advanced medical or surgical therapy
or both in the following one year, (4) they had other
major systemic diseases requiring hospitalization or
operation in the following one year, or (5) they were
unable or unwilling to be followed up during the follow-
ing one year period. Additionally, patients with life
expectancy of <6 months (e.g., malignant metastatic
neoplasm), and those receiving treatment with immuno-
suppressive agents were also excluded.
Clinical follow up for adverse cardiovascular events
According to the study protocol, each patient with
initially stable conditions under medical treatment is
prospectively and regularly followed up in the individual
hospital clinics. After enrollment, follow-up data collec-
tion will be taken during outpatient clinic visit, if applic-
able, and approximately every 3 months for the first year
and every 6 months starting from the second year after
enrollment. Medication is prescribed for each patient
individually at the discretion of the treating physician.
During follow-up, the occurrence of adverse CV events
will be recorded, including all cause deaths, cardiovascular
death, nonfatal myocardial infarction, nonfatal stroke,
unplanned revascularization procedures, unplanned
hospitalization for refractory or unstable angina, and for
other causes including stroke, transient ischemic at-
tack, heart failure, or peripheral arterial occlusive
disease. Myocardial infarction is confirmed if ischemic
symptoms presented with elevated serum cardiac en-
zyme levels and/or characteristic ECG changes. Cor-
onary revascularization procedures with either PCI or
coronary artery bypass grafting surgery are confirmed
by medical record review. Stroke is confirmed if there
is a new neurologic deficit lasting for at least 24 h
with definite imaging evidence of cerebrovascular ac-
cident either by MRI or CT scan. The protocol for
CV event follow-up is similar to that has been
reported in our previous works [10, 11]. Besides, for
the second track of long-term follow-up, the assess-
ment of clinical events will be also conducted by some
independent national data banks if the patients agree.
Baseline data collection
Personal and clinical profiles at enrollment
After enrollment, specially trained study nurses and
qualified cardiologists collected all data prospectively
whenever feasible. Baseline characteristics including risk
factors such as history of hypertension, diabetes, smok-
ing habit, as well as medications history were collected.
Variable medications and dosage information were
collected by chart review and structured questionnaire.
Biochemical profiles including blood glucose, lipid pro-
file and kidney function were recorded. In addition,
healthy lifestyle factors were noted, including a healthy
diet, abstinence from smoking, and regular exercise
habit. A healthy diet was identified according to the Rec-
ommended Food Score, developed in 2000 by Kant et al.
[12] which contains more fruits, vegetables, legumes,
nuts, reduced-fat dairy products, whole grains, and fish.
Abstinence from smoking applied to those whonever
smoked, or had quit smoking for more than 6 months.
Regular exercise denotes exercise episodeslasting for at
least 30 min, more than five times a week.
Personality assessment
In addition to baseline biochemical data and lifestyle in-
formation collected, all patients were asked to complete
the Type D Scale for Taiwan (DS14-T) after enrollment.
This version was translated from DS14 and has been
validated for the Taiwanese population [9]. The reliability
of Type D assessment in Taiwan is good, with
Cronbach’s α for negative affectivity and social inhibition
of 0.86 and 0.79 respectively, [13] and adequate con-
struct validity and can be considered equivalent to the
Taiwanese version [13]. In short, this instrument is a
measure of negative affectivity (e.g., “I often make a fuss
about unimportant things” and “I take a gloomy view of
things”) and social inhibition (e.g., “I make contact easily
when I meet people” and “I find it hard to start a
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conversation”) with seven five-point Likert-scaled items
ranging from 0 = false to 4 = true for each subscale and
is regarded as the current standard for identifying the
Type D pattern [14]. Patients scoring high on both
subscales, according to a standardized cut-off score ≥ 10,
are classified as having a Type D personality [15].
Blood and urine sampling
After enrollment, 20 mL of blood from peripheral
vessels and 10 mL urine were collected. Sampling
collection was at the time of enrollment, and every
3 months thereafter in 3-month intervals during out-
patient clinic visits. These samples were stored in a −80 °C
refrigerator until analysis for biomarkers and metabo-
lomic study. Patients were excluded if they had
ingested any drugs with antioxidant activity, vitamins,
or food additives within the 4 weeks prior toblood/
urine sampling.
Established and new BiomarkerMeasurement
Established biochemical markers for atherosclerotic
cardiovascular disease
Biological markers provide quantitative information
reflecting biological processes, disease state, or re-
sponse to treatment in disease management. In the
current study, we undertake to investigatea series of
established biochemical markers, including but not
limited to, the following: (1) high sensitivity C−React-
ive Protein (hsCRP); (2) Adiponectin; (3) Matrix
Metalloproteinase-3; (4) Matrix Metalloproteinase-9;
(5) Interleukin-6; (6) Fibrinogen; (7) Lp-PLA2; (8)
Tumor Necrosis Factor-α. Besides these established
biochemical markers we attempted to validate another
series ofnew potential bio-signature markers for
cardiovascular disease.
New inflammatory biomarkers for cardiovascular disease
Biochemical marker spotentially associated with the
atherosclerosis processwere selected, in particular those
related to inflammation including but not limited to the
following: (1) Fatty Acid Binding Protein; (2) soluble
Vascular Cellular Adhesion Molecule-1; (3) soluble
Intercellular Adhesion Molecule-1; (4) Carbohydrate
Antigen 125; (5) Monocyte Chemotactic Protein-1; (6)
Cardiac Troponin I; (7) CK-MB; (8) NT-proBNP; (9)
C-type Natriuretic Peptide; (10) Fetal Heart Binding
Protein; (11) Neutrophil Gelatinase-Associated Lipocalin;
(12) Chemokine (C-X-C motif) ligand 6; (13) Chemokine
(C-X-C motif) ligand 16; (14) Tumor Necrosis Factor
ligand superfamily member 14; (15) Oncostatin M; and
(16) Myeloperoxidase.
Both the above established and potentially newbiomar-
kers will be measured sequentially to determine any cor-
relation with the development of future clinical events
once the adequate clinical outcomes are identified in the
next 5 years.
Metabolomic study for novel biomarkers
The plasma and urine samples will be frozen in liquid
nitrogen immediately and stored at −80 °C to prevent
any metabolic decay until further metabolomic analysis.
Once more than 50 major cardiovascular events have
been identified during follow-up, which may take around
2 years for the initially enrolled 1000 study patients, the
metabolomic studies of the plasma and urine will be
chronologically performed in the matched CAD cases
with major cardiovascular events and those without
events during the follow-up period. The biological path-
ways and clinical biomarkers valuable for predicting the
major cardiovascular events of atherosclerotic vascular
diseases will be investigated.
Qualitative and quantitative UHPLC -QTOF, GC-MS,
LC-QQQ and GCXGC-TOF-MS analysis will be
performed at the Metabolomics Core Laboratory. To
confirm identified metabolite markers, we will develop a
highly sensitive and specific isotope dilution GC-MS or
LC-MS method for accurately quantifying the metabolite
from biospecimens. Concentration of target markers will
be accurately quantified.
Statistics
A comparison will be drawn between subjects with exist-
ing CVD and those who newly develop cardiovascular
events during the follow-up period. Quantitative vari-
ables will be expressed as mean and standard deviation
in the presence of normal or median distribution, and
interquartile range in the presence of asymmetric distri-
bution. Qualitative variables will be presented in both
absolute frequencies (number of patients) and relative
frequencies (percentage). Comparisons of continuous
variables between groups will beperformed by ANOVA
test, while subgroup comparisons of categorical variables
will be assessed by χ2 or Fisher’s exact test. The primary,
secondary, and tertiary outcomes will be described by an
overall percentage, taking all centers into consideration,
and the percentage described in each center. These will
also be expressed by means of proportions and their
confidence intervals of 95%. Where there is great vari-
ability in prescription, a weighted average variance at
each center will be generated. For regression models, we
will report the odds ratio (logistic regression) or hazard
ratio (for the regression of Cox proportional hazards),
the corresponding standard error, the confidence inter-
vals of 95%, and p values. Additionally, we will report
the p values up to three decimals; however, places with p
values below 0.001 are reported as p < 0.001. In all the
tests, we will use the two-tailed alpha significance level
of 0.05.
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Baseline data of initial 1663 patients enrolled
Baseline patient characteristics
In this study, up to 2500 patients would be enrolled over
5 years according to the schedule. From September 2012
to December 2014, initial 1663 patients with a history of
PCI have been successfully enrolled in the first 2.5 years.
All patients gave written informed consent before
participating in the study. Among them, 1429 (85.93%)
were male, 602 (36.22%) had diabetes; 1078 (64.82%)
had hypertension; 932 (56.04%) were smokers and 340
(20.44%) had a family history of HCVD. The baseline
characteristics of the overall population are provided
in Table 1.
As to the target lesion of coronary artery disease,
43.63% involved the left anterior descending artery,
27.29% the right coronary artery and 14.9% the left cir-
cumflex artery. Among the stent information collected,
the mean stent diameter was 2.64 ± 0.68 mm with an
average length of 21.99 ± 6.92 mm. An echocardiogram
was performed in 1014 (61%) of the 1663 CAD
patients and their mean left ventricular ejection
fraction (58.67 ± 21.7%) was in the normal range.
Baseline biochemical profiles
Table 2 shows the baseline parameters and biochemical
profiles of CAD patients enrolled in this cohort. Total
cholesterol was 163.51 ± 36.99 mg/dL and low-density
lipoprotein (LDL) cholesterol was 95.21 ± 29.98 mg/dL,
showing these patients were treated well and the average
LDL value achieved the ATP III/NCEP target of optimal
Table 1 Baseline demographic data of CAD patients enrolled till
December 2014
Number of patients 1663
Age at enrollment, yrs 63.49 ± 11.89
Male, n (%) 1429 (85.93)
Body mass index, (kg/m2) 26.58 ± 4.4
Waist, cm 93.68 ± 10
Buttocks, cm 99.45 ± 8.57
Waist/buttocks ratio 0.94 ± 0.08
Systolic blood pressure, mmHg 129.82 ± 17.2
Diastolic blood pressure, mmHg 74.85 ± 11.89
Hypertension, n (%) 1078 (64.82)
Diabetes, n (%) 602 (36.22)
Smoking, n (%) 932 (56.04)
Family history of CAD 340 (20.44)
Previous ischemic stroke, n (%) 50 (3.01)
Target lesion in coronary artery (n = 1114)
Left main artery, n (%) 20 (1.80)
Left anterior descending artery, n (%) 486 (43.63)
Left circumflex artery, n (%) 166 (14.90)
Right coronary artery, n (%) 304 (27.29)
Diameters and length of stents (n = 971)
Stent Diameters, mm
Mean ± SD 2.64 ± 0.68
Median (IQR) 3 (2–3)
Stent length, mm
Mean ± SD 21.99 ± 6.92
Median (IQR) 22 (18–26)
Left ventricular EF, % (n = 1014)
Mean ± SD 58.67 ± 21.7
Median (IQR) 61 (51–69)
CAD coronary artery disease, EF ejection fraction (calculated by
echocardiography or ventriculography), mm minimeter, n patient number, SD
standard deviation
Table 2 Baseline blood biochemical profile at enrollment
Glucose, mg/dL
Mean ± SD 120.22 ± 42.96
Median (IQR) 107 (95–131)
Cholesterol, mg/dL
Mean ± SD 163.51 ± 36.99
Median (IQR) 158 (137–185)
LDL-cholesterol, mg/dL
Mean ± SD 95.21 ± 29.98
Median (IQR) 91 (74–112.2)
HDL-cholesterol, mg/dL
Mean ± SD 41.63 ± 10.51
Median (IQR) 40 (34–47)
Triglyceride, mg/dL
Mean ± SD 139.76 ± 88.31
Median (IQR) 116 (84–169)
Serum creatinine, mg/dL
Mean ± SD 1.3 ± 1.3
Median (IQR) 1.02 (0.86–1.25)
eGFR
Mean ± SD 76.72 ± 31.05
Median (IQR) 75.66 (60.05–92.63)
White blood cells,/CUMM
Mean ± SD 7556.08 ± 2345.17
Median (IQR) 7145 (5990–8600)
Hemoglobin, g/dL
Mean ± SD 13.73 ± 1.83
Median (IQR) 13.9 (12.7–15)
Platelet,/CUMM
Mean ± SD 215254.96 ± 55152.1
Median (IQR) 211000 (176000–250000)
eGFR estimated glomerular fraction rate, HDL high density lipoprotein, LDL low
density lipoprotein
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LDL level (<100 mg/dL) [16, 17]. The values of serum
high-density lipoprotein (HDL)- cholesterol and tri-
glyceride were 41.63 ± 10.51 mg/dL and 139.76 ±
88.31 mg/dL, respectively.
Baseline medication profiles
Table 3 presents the medication used in thestudy cohort.
Anti-platelet agents were prescribed in 93% of patients;
anticoagulant in 15.88%; Beta-blocker in 64.86%;
diuretics in 13.29%; dihydropyridine (DHP) calcium
channel blockers in 32.79%; calcium-blockers (non-
DHP) in 37.20%, and RAS blocking agents [angiotensin-
converting enzyme (ACE) inhibitors or angiotensin
receptor blockers (ARBs) in 62.56%. To our interest,
although statin was suggested for all patients with cor-
onary disease, only 73.67% of patients took statin during
enrollment. Furthermore, proton pump inhibitors were
prescribed in 5.25%. All data will be analyzed for drug
interactions in the future.
Baseline lifestyleand dietary supplementprofiles
To further investigate the effect of lifestyle modification
strategies and physiological personality in mitigating
future risk, exercise habit and whether diet control
followed the ATP III guideline were recorded andare
shown in Table 4. Of the study patients, 64.05% were on
diet control following the recommendations of ATP III
for CAD patients. Exercise frequency has been reported
by 886 (51.74%) of enrolled patients, with 54.42% report-
ing more than 30 min of moderate-intensity exercise
5 days a week. Additional information regarding dietary
supplements as well as Chinese medicinal herbs is
also shown in Table 4. Dietary supplements were
reported by557 (33.53%) study patients, with 446
(79.50%) taking cornmeal, 19.03% taking fish oil,
5.76% Anka, 5.40% Gingko; 5.92% Natto and 5.23%
shark cartilage. The incidence of type D personality
was 9.63% in the study patients.
Discussion
In recent decades, atherosclerosis CV disease has be-
come one of the leading causes of morbidity and mortal-
ity in the world. Despite great efforts to reduce risk
including medical or primary prevention strategies, the
risk remains high and new therapeutic strategies are still
needed both in the western and the Asian patients. The
current study aims to provide detailed information about
long-term outcome in secondary prevention for stable
patients with coronary intervention. Besides, it also aims
to investigate possible new markers either independently
or concomitantly pointing to the occurrence of adverse
cardiovascular events. Findings from this study will not
only provide new indicators of potential association be-
tween secondary prevention and future adverse events
but also help to improve our understanding about the
effective therapeutic targets as well as strategy to retard or
prevent the progression of disease after revascularization.
Among the contemporary pharmacological therapeutic
strategy, statins have been clearly shown to be poten-
tially lifesaving medications and are widely used in
patients with CV disease. Secondary and primary
Table 3 Medication treatment at enrollment
Anti-platelet, n (%) 1540 (93)
Anti-coagulant, n (%) 263 (15.88)
ACE-inhibitor, n (%) 356 (21.50)
ARB, n (%) 686 (41.43)
ACE inhibitor/ARB, n (%) 1036 (62.56)
Beta-blockers, n (%) 1074 (64.86)
Calcium-blocker, n (%) 616 (37.20)
Calcium-blocker (DHP), n (%) 543 (32.79)
Diuretics, n (%) 220 (13.29)
Oral nitrates, n (%) 753 (45.47)
Statin, n (%) 1220 (73.67)
PPI, n (%) 87 (5.25)
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, DHP
dihydropyridine, PPI proton pump inhibitor
Table 4 Diet, life style, and personality information of study
cohort
Diet control following NECP guidelines for
patients with CAD, n (%)
1053 (64.05)
Regular exercise habit, n (%) 860 (51.74)
Exercise frequency
< 1 times/week, n (%) 63 (7.33)
1–2 times/week, n (%) 123 (14.30)
3–5 times/week, n (%) 198 (23.02)
> 5 times/week, n (%) 468 (54.42)
Use of Chinese medicinal herbs and dietary
supplement, n (%)
557 (33.53)
Anka, n (%) 32 (5.76)
Fish oil, n (%) 106 (19.03)
Phytosterols or other stanols, n (%) 3 (0.54)
Cornmeal, n (%) 446 (79.50)
Gingko, n (%) 30 (5.40)
Natto, n (%) 33 (5.92)
Garlic essence, n (%) 11 (1.98)
Grape seed, n (%) 13 (2.35)
Grapefruit juice, n (%) 8 (1.44)
Shark cartilage, n (%) 29 (5.23)
Fur seal oil 6 (1.08)
Type D personality, n (%) 160 (9.63)
CAD coronary artery disease
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prevention trials have demonstrated that lipid lowering
with statin can reduce morbidity and mortality of CV
disease in both western and Asian (mainly Japanese)
cohorts [18–20]. Further, a target of serum LDL level
<70 mg/dL has been suggested for very high-risk
patients according to the findings of some clinical trials
mainly in western cohorts [21]. Recently, the 2013 ACC/
AHA cholesterol guidelines further identified patients in
the four statin benefit groups which included clinical
atherosclerotic cardiovascular disease (ASCVD),
diabetes, high LDL level (>190 mg/dL) and those with
an ASCVD score ≥7.5%, [22] indicating the importance
of statin therapy in CV protection. However, most of the
above therapeutic strategy and targets are set mainly for
western patients. Given the lack of adequate evidence, it
is not known if these guidelines could be also feasible to
the clinical implication in Asian especially ethnic
Chinese cohorts. In this study, while 93% of the study
patients received at least one antiplatelet including
aspirin and others, there are 73% of the patients on
regular statin treatment in this study. The baseline mean
plasma LDL level is around 95 mg/dL either with or
without statin treatment, which remains higher than the
recommended target in patients with established CV dis-
ease (≤70 mg/dL). However, it is similar to the LDL
values reported in the recently published European
registry for secondary prevention study (CICD-PIOT), in
which the LDL value is around 91.6 to 110.4 mg/dL,
[23] revealing the LDL level for secondary prevention in
the real world nowadays. Furthermore, a previous lipid
registry for CV disease in Taiwan has reported the
achieved mean LDL cholesterol level was 101.49 mg/dL
in another secondary prevention CAD cohort during
2010 and 2011 [24]. In fact, the Taiwanese national in-
surance reimbursement policy have recommended to
keep serum total cholesterol level <170 mg/dL and the
serum LDL level <100 mg/dL for secondary prevention
cohort since 2013. It is clearly demonstrated that the
cholesterol control by statin use, as recommended by
either global lipid guidelines or national insurance reim-
bursement policy, has much improved in Taiwan in the
last 5 years. Similar findings of the trend of increasing
statin use have also been observed in other cohort
studies. Park et al. investigated the long-term outcome of
left main coronary artery intervention classified by time
periods: wave 1 (1995–1998), wave 2 (2003–2006), and
wave 3 (2007–2010). The prescription rate of statins has
progressively increased from 18.1% (wave 1), to 64.5%
(wave 2) and 91.7% (wave3), [25], which confirmed the
changing concept of stain use in CAD patients.
Renin-angiotensin system (RAS) is an important medi-
ator of blood volume, arterial pressure, and cardiac and
vascular function in CV system. RAS blocking agents
(including ACE inhibitors and ARBs) can prevent CV
disease by lowering blood pressure and by vascular pro-
tection. They have therefore been suggested as the first-
line treatment for CV patients with target organ damage.
The benefits of RAS blocking agents in the primary and
secondary prevention of CAD have been well established
[26]. In the current study, while the achieved systolic
(130 mmHg) and diastolic blood pressure (75 mmHg)
are quite acceptable, the use of renin-angiotensin system
(RAS) blocking agents (ACE inhibitors and ARBs) and
beta adrenergic blockers are above 60%. Besides, the
higher prescription rate of ARBs than that of ACE inhib-
itors has been also observed in the Biosignature CAD
cohort, which is probably due to the better tolerance of
ARB use in the Asian population. Interestingly, the in-
creasing use of ACE inhibitor/ARB was also observed in
Park’s 25 year-observation, with an increase from 11.9%
(wave 1) to 26% (wave 3), supporting the importance of
the use of RAS blocking agents in CAD patients [25].
The high prescription rate of ACE inhibitor/ARB in the
Biosignature CAD cohort reflects the improvement of
evidence-based treatment in CV disease, which is also
essential to the improvement of long-term outcome in
high-risk CAD patients.
Notably, while the classic risk factors such as lipid pro-
file, blood pressure, and blood sugar have been ad-
equately controlled, the risk of developing a future event
may remain high especially in the high-risk CAD
patients. Given the potential importance of inflammation
in the development and progression of atherosclerosis
CV disease, other non-classic risk factors such as life-
style and environment exposure that might directly or
indirectly lead to vascular inflammation/injury should be
considered. There is no clear information for the role of
lifestyle in secondary prevention for high-risk CAD
patients after PCI. Thus, in this study, lifestyle data is
collected, which will be investigated to evaluate the po-
tential impact of healthy lifestyle factors including
healthy diet, nonsmoking and active exercise on long-
term clinical outcomes of the CAD patients. Given the
popularity of healthy food not only in western world but
also in Asian countries, we also incorporated patient
data regarding the use of Chinese medicinal herbs and
dietary supplements into the biosignature CAD cohort
study. In contrast to the well-known nutrients, these
supplements are complex and many potential mecha-
nisms including antioxidant properties, regulation of the
inflammatory response, and the proliferation/differenti-
ation of immune cells have been proposed for them. To
our interest, there have been few data about the CV ben-
efits of Chinese medical herbs and supplements in CAD
patients. In this cohort study, the use of Chinese medical
herbs and supplements will be systemically evaluated to
provide advanced clues for their potential impact on
secondary prevention in CAD patients.
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In addition to lifestyle factors, personality trait such as
type D personality was included in this study. Personality
traits, such as type A (high strung), type B (easy going),
and type D (distressed type), have been reported to be
variously associated with different CV diseases [27–29].
Recent evidence has pointed to closer connections of
personality traits, especially type D personality, with CV
diseases. Type D personality represents the effects of
two personality traits: negative affectivity (NA, the
tendency to experience negative emotions) and social in-
hibition (SI, the tendency to inhibit the expression of
emotions [30]. It has been observed that type D person-
ality might be associated with poor clinical outcomes in
patients with congestive heart failure or peripheral
arterial occlusive disease, after receiving open heart
surgery and after receiving an implantable cardioverter-
defibrillator [31]. Accordingly, type D personality may be
considered an important risk factor that should be taken
into account for risk stratification in some CV diseases.
So far, the majority of the international studies on type
D personality have indicated that the prevalence of type D
personality is between 15 and 29% in CV patients [32, 33].
However, the prevalence of type D personality and its role
in long-term outcome in an Asian population remains
undetermined. According to the current baseline data, the
prevalence of type D personality is around 9 ~ 10% in our
study patients. Our study may provide important informa-
tion on psychological issues in CAD patients.
Finally and most importantly, in this study, serial
blood samples will be collected both at baseline and
during regular follow-up to evaluate the baseline and the
dynamic changes of inflammatory biomarkers for the
development of clinical outcomes. The classic and well-
established serum biomarkers including hs-CRP and
others will be evaluated for both confirmation and
comparison. On the other hand, serial new inflammatory
biomarkers such as some cytokines, chemokines and in-
flammatory ligands that are less related to clinical
atherosclerosis disease will be evaluated to identify their
potential prognostic role for clinical outcomes in our
CAD patients. The new biomarkers that could improve
the prognostic value of well-established biomarkers such
as hs-CRP will be further investigated. Once the clinical
significance could be confirmed by replication, further
new projects will be initiated with both in vitro and in
vivo experiments to identify the potential mechanisms
and new therapeutic targets. Besides, to further define
the novel biosignatures as well as novel mechanisms, an-
other line of metablomic study will be also done in
selected cases in this study. Taken together, our study
focused on secondary prevention to identify the new pre-
dictors and to investigate the potential mechanisms and
novel therapeutic target in stable patients after PCI even
when they are already under contemporary treatment.
Study limitations
Although the criteria for patient enrollment and the
protocol for clinical follow-up have been clearly defined
and all cases are recruited by well-train staffs in teaching
hospitals, selection bias arising from clinical profile, in-
vestigator participation and treatment adherence by
patients could not be completely excluded. Furthermore,
according to the population distribution, the patients are
extensively recruited throughout the whole country in
order to represent the people living in Taiwan. However,
this is a hospital-based rather than a community-based
study. Further investigations may be required to eluci-
date and adjust the potential geographic variations in
therapeutic principle, environmental exposure, patient
behavior, and so on. Besides, given the long-term follow-
up, a substantial portion of patients may be lost to
follow up. Thus, the clinical outcomes of the patients
will be also periodically assessed through some national
data banks such as the national insurance policy data
bank in Taiwan if indicated.
Conclusions
The biosignature CAD study is a nationwide prospective
cohort study aiming to investigate new biosignatures to
identify the CAD patients at very high risk in an Asian
cohort. Given the comprehensive network in Taiwan, all
the patients could be enrolled and closely followed up
for 5 years to assess impacts of the classic and non-
classic risk factors as well as the standard and novel
biomarkers on future clinical events. As the study is
ongoing, the baseline data revealed that the patients are
in stable condition by standard contemporary treatment
at enrollment. The investigation on new biosignatures
including inflammatory markers, personality traits and
environment factors will further improve our under-
standings of the complex atherosclerosis disease and
advance the therapeutic strategies of stable CAD in
Asian patients especially the ethnic Chinese in Taiwan.
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